Comparing the current results to its competitors, Skinvisible Inc reported Revenue decrease in the 2 quarter 2026 year on year by 0 %, despite the revenue increase by the most of its competitors of 1.86 %, recorded in the same quarter.
Skinvisible Inc 's Comment on Competition and Industry Peers
The company encounters limited direct competition for Invisicare and its patented topically administered skin products in terms of performance capabilities. Several companies are pursuing unique delivery systems and acquiring firms with delivery technology. Competitors may have longer operating histories, greater resources, stronger brand recognition, and larger customer bases. They may also implement more aggressive pricing strategies and invest more heavily in development, marketing, and sales. To maintain competitiveness, the company needs to invest substantially in sales and marketing but may face resource constraints that could impact its ability to develop technological advances and affect its business and profitability.
Biofrontera Inc is a pharmaceutical company that specializes in developing and commercializing dermatological treatments for various skin conditions. Their business model revolves around research and development to create innovative products, obtaining regulatory approvals, and marketing and selling their products globally through direct sales teams and distribution partnerships. They aim to provide patients with effective and safe dermatological treatments while generating revenues through product sales.
Incyte Corporation is a biopharmaceutical company that primarily focuses on the research, development, and commercialization of innovative medicines targeting oncology and serious inflammatory conditions. Their business model emphasizes robust R&D investments to discover potential drug candidates, often engaging in collaborations with other organizations to enhance their development capabilities. Incyte leverages its extensive intellectual property portfolio to protect and maximize the value of its therapeutic advancements in the market.
Gt Biopharma Inc's business model revolves around developing innovative immunotherapies for the treatment of various cancers. The company focuses on harnessing the power of the immune system to target and eliminate cancer cells through its proprietary technology platform. Gt Biopharma Inc aims to advance its therapies through clinical trials and ultimately commercialize them for the benefit of patients worldwide.
Evolus Inc is a pharmaceutical company that operates in the field of aesthetics, with a primary focus on developing and commercializing minimally invasive treatments for patients. Their business model revolves around researching and developing innovative neurotoxin products to address various facial aesthetic concerns. The company aims to bring their products to market through strategic partnerships with healthcare professionals and providers, ensuring widespread accessibility and utilization.
Aclaris Therapeutics Inc is a company that focuses on developing and commercializing innovative therapies to address significant unmet needs in dermatology and immunology. Their business model involves researching and developing treatments for various skin and hair conditions, obtaining regulatory approvals, and marketing these therapies to healthcare professionals and patients.
Sources:
Skinvisible Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Skinvisible Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
